MY18B_HUMAN
ID MY18B_HUMAN Reviewed; 2567 AA.
AC Q8IUG5; A0A075B6F5; B2RWP3; F5GXR6; F5GYU7; Q8NDI8; Q8TE65; Q8WWS0; Q96KH2;
AC Q96KR8; Q96KR9;
DT 11-JUL-2003, integrated into UniProtKB/Swiss-Prot.
DT 28-MAR-2018, sequence version 2.
DT 03-AUG-2022, entry version 170.
DE RecName: Full=Unconventional myosin-XVIIIb;
GN Name=MYO18B;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 1 AND 2), VARIANTS
RP VAL-234; ASN-347; GLN-379; CYS-389; MET-590; GLY-835; LEU-1095; GLN-1195;
RP GLN-1238; THR-1238; LYS-1708; ASP-1715; GLU-1970; CYS-2295; HIS-2381 AND
RP GLU-2554, AND POSSIBLE ROLE IN TUMOR SUPPRESSION.
RC TISSUE=Skeletal muscle;
RX PubMed=12209013; DOI=10.1073/pnas.192445899;
RA Nishioka M., Kohno T., Tani M., Yanaihara N., Tomizawa Y., Otsuka A.,
RA Sasaki S., Kobayashi K., Niki T., Maeshima A., Sekido Y., Minna J.D.,
RA Sone S., Yokota J.;
RT "MYO18B, a candidate tumor suppressor gene at chromosome 22q12.1, deleted,
RT mutated, and methylated in human lung cancer.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:12269-12274(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), CHARACTERIZATION, AND
RP VARIANTS ARG-661 AND LEU-925.
RC TISSUE=Skeletal muscle;
RX PubMed=12547197; DOI=10.1016/s0022-2836(02)01335-9;
RA Salamon M., Millino C., Raffaello A., Mongillo M., Sandri C., Bean C.,
RA Negrisolo E., Pallavicini A., Valle G., Zaccolo M., Schiaffino S.,
RA Lanfranchi G.;
RT "Human MYO18B, a novel unconventional myosin heavy chain expressed in
RT striated muscles moves into the myonuclei upon differentiation.";
RL J. Mol. Biol. 326:137-149(2003).
RN [3]
RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS CYS-547; ARG-661 AND
RP GLN-1119.
RA Gu Y., Ji Y., Penn S.G., Hanzel D.K., Rank D.R., Chen W., Shannon M.E.;
RT "Myosin-like gene expressed in human heart and muscle.";
RL Submitted (JAN-2002) to the EMBL/GenBank/DDBJ databases.
RN [4]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX PubMed=10591208; DOI=10.1038/990031;
RA Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M., Clamp M.,
RA Smink L.J., Ainscough R., Almeida J.P., Babbage A.K., Bagguley C.,
RA Bailey J., Barlow K.F., Bates K.N., Beasley O.P., Bird C.P., Blakey S.E.,
RA Bridgeman A.M., Buck D., Burgess J., Burrill W.D., Burton J., Carder C.,
RA Carter N.P., Chen Y., Clark G., Clegg S.M., Cobley V.E., Cole C.G.,
RA Collier R.E., Connor R., Conroy D., Corby N.R., Coville G.J., Cox A.V.,
RA Davis J., Dawson E., Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M.,
RA Ellington A.G., Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S., Hunt S.E.,
RA Jones M.C., Kershaw J., Kimberley A.M., King A., Laird G.K., Langford C.F.,
RA Leversha M.A., Lloyd C., Lloyd D.M., Martyn I.D., Mashreghi-Mohammadi M.,
RA Matthews L.H., Mccann O.T., Mcclay J., Mclaren S., McMurray A.A.,
RA Milne S.A., Mortimore B.J., Odell C.N., Pavitt R., Pearce A.V., Pearson D.,
RA Phillimore B.J.C.T., Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y.,
RA Rogers L., Ross M.T., Scott C.E., Sehra H.K., Skuce C.D., Smalley S.,
RA Smith M.L., Soderlund C., Spragon L., Steward C.A., Sulston J.E.,
RA Swann R.M., Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J., Shintani A.,
RA Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S., Roe B.A., Chen F., Chu L.,
RA Crabtree J., Deschamps S., Do A., Do T., Dorman A., Fang F., Fu Y., Hu P.,
RA Hua A., Kenton S., Lai H., Lao H.I., Lewis J., Lewis S., Lin S.-P., Loh P.,
RA Malaj E., Nguyen T., Pan H., Phan S., Qi S., Qian Y., Ray L., Ren Q.,
RA Shaull S., Sloan D., Song L., Wang Q., Wang Y., Wang Z., White J.,
RA Willingham D., Wu H., Yao Z., Zhan M., Zhang G., Chissoe S., Murray J.,
RA Miller N., Minx P., Fulton R., Johnson D., Bemis G., Bentley D.,
RA Bradshaw H., Bourne S., Cordes M., Du Z., Fulton L., Goela D., Graves T.,
RA Hawkins J., Hinds K., Kemp K., Latreille P., Layman D., Ozersky P.,
RA Rohlfing T., Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K.,
RA Nelson J., Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S., Budarf M.L.,
RA McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E., Edelmann L., Kim U.J.,
RA Shizuya H., Simon M.I., Dumanski J.P., Peyrard M., Kedra D., Seroussi E.,
RA Fransson I., Tapia I., Bruder C.E., O'Brien K.P., Wilkinson P.,
RA Bodenteich A., Hartman K., Hu X., Khan A.S., Lane L., Tilahun Y.,
RA Wright H.;
RT "The DNA sequence of human chromosome 22.";
RL Nature 402:489-495(1999).
RN [5]
RP NUCLEOTIDE SEQUENCE [MRNA] OF 2343-2567.
RC TISSUE=Skeletal muscle;
RA Stanchi F., Lanfranchi G.;
RT "Full-length sequencing of 100 cDNA clones from human adult skeletal
RT muscle.";
RL Submitted (FEB-2000) to the EMBL/GenBank/DDBJ databases.
RN [6]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS CYS-547;
RP ARG-661; GLN-1119 AND ARG-2347.
RX PubMed=15489334; DOI=10.1101/gr.2596504;
RG The MGC Project Team;
RT "The status, quality, and expansion of the NIH full-length cDNA project:
RT the Mammalian Gene Collection (MGC).";
RL Genome Res. 14:2121-2127(2004).
RN [7]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2359-2567.
RC TISSUE=Testis;
RX PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA Wiemann S., Schupp I.;
RT "The full-ORF clone resource of the German cDNA consortium.";
RL BMC Genomics 8:399-399(2007).
RN [8]
RP POSSIBLE INVOLVEMENT IN SUPPRESSION OF CELL ANCHORAGE-INDEPENDENT GROWTH.
RX PubMed=12741677; DOI=10.1023/a:1022978932215;
RA Yokota J., Nishioka M., Tani M., Kohno T.;
RT "Genetic alterations responsible for metastatic phenotypes of lung cancer
RT cells.";
RL Clin. Exp. Metastasis 20:189-193(2003).
RN [9]
RP IDENTIFICATION BY MASS SPECTROMETRY.
RC TISSUE=Lymphoblast;
RX PubMed=14654843; DOI=10.1038/nature02166;
RA Andersen J.S., Wilkinson C.J., Mayor T., Mortensen P., Nigg E.A., Mann M.;
RT "Proteomic characterization of the human centrosome by protein correlation
RT profiling.";
RL Nature 426:570-574(2003).
RN [10]
RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC TISSUE=Platelet;
RX PubMed=18088087; DOI=10.1021/pr0704130;
RA Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT "Phosphoproteome of resting human platelets.";
RL J. Proteome Res. 7:526-534(2008).
RN [11]
RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1829, AND IDENTIFICATION BY
RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC TISSUE=Cervix carcinoma;
RX PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA Elledge S.J., Gygi S.P.;
RT "A quantitative atlas of mitotic phosphorylation.";
RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN [12]
RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC TISSUE=Leukemic T-cell;
RX PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA Rodionov V., Han D.K.;
RT "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT reveals system-wide modulation of protein-protein interactions.";
RL Sci. Signal. 2:RA46-RA46(2009).
RN [13]
RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1216; SER-2193; SER-2296;
RP SER-2309 AND SER-2377, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP ANALYSIS].
RC TISSUE=Erythroleukemia;
RX PubMed=23186163; DOI=10.1021/pr300630k;
RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA Mohammed S.;
RT "Toward a comprehensive characterization of a human cancer cell
RT phosphoproteome.";
RL J. Proteome Res. 12:260-271(2013).
RN [14]
RP INVOLVEMENT IN KFS4.
RX PubMed=25748484; DOI=10.1136/jmedgenet-2014-102964;
RA Alazami A.M., Kentab A.Y., Faqeih E., Mohamed J.Y., Alkhalidi H.,
RA Hijazi H., Alkuraya F.S.;
RT "A novel syndrome of Klippel-Feil anomaly, myopathy, and characteristic
RT facies is linked to a null mutation in MYO18B.";
RL J. Med. Genet. 52:400-404(2015).
CC -!- FUNCTION: May be involved in intracellular trafficking of the muscle
CC cell when in the cytoplasm, whereas entering the nucleus, may be
CC involved in the regulation of muscle specific genes. May play a role in
CC the control of tumor development and progression; restored MYO18B
CC expression in lung cancer cells suppresses anchorage-independent
CC growth.
CC -!- SUBUNIT: Homodimer. May interact with F actin through the GPA motif
CC (Gly/Pro/Ala-rich).
CC -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cytoplasm, myofibril,
CC sarcomere. Note=Punctate pattern in undifferentiated myoblasts.
CC Nuclear, on primary cardiomyocytes and adult muscle. A partial
CC sarcomeric location was found in some cardiomyocytes.
CC -!- ALTERNATIVE PRODUCTS:
CC Event=Alternative splicing; Named isoforms=3;
CC Name=1;
CC IsoId=Q8IUG5-1; Sequence=Displayed;
CC Name=2;
CC IsoId=Q8IUG5-2; Sequence=VSP_007764, VSP_007765;
CC Name=3;
CC IsoId=Q8IUG5-3; Sequence=VSP_059434;
CC -!- TISSUE SPECIFICITY: Selectively expressed in cardiac and skeletal
CC muscles. Weakly expressed in testis, pancreas, placenta, prostate, lung
CC and thymus.
CC -!- DEVELOPMENTAL STAGE: Reaches an expression peak in the third day after
CC induction and remains at similar level during successive myotubule
CC maturation.
CC -!- DISEASE: Klippel-Feil syndrome 4, autosomal recessive, with nemaline
CC myopathy and facial dysmorphism (KFS4) [MIM:616549]: A form of Klippel-
CC Feil syndrome, a skeletal disorder characterized by congenital fusion
CC of cervical vertebrae. It is due to a failure in the normal
CC segmentation of vertebrae during the early weeks of fetal development.
CC The clinical triad consists of short neck, low posterior hairline, and
CC limited neck movement. KFS4 features additionally include myopathy,
CC mild short stature, microcephaly, and distinctive facies.
CC {ECO:0000269|PubMed:25748484}. Note=The disease is caused by variants
CC affecting the gene represented in this entry.
CC -!- MISCELLANEOUS: Frequently deleted, mutated, and hypermethylated in lung
CC cancers.
CC -!- SIMILARITY: Belongs to the TRAFAC class myosin-kinesin ATPase
CC superfamily. Myosin family. {ECO:0000305}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; AB075376; BAC16363.1; -; mRNA.
DR EMBL; AB042648; BAB55550.2; -; mRNA.
DR EMBL; AJ310931; CAC70712.2; -; mRNA.
DR EMBL; AJ310932; CAC70714.3; -; Genomic_DNA.
DR EMBL; AY077700; AAL75811.1; -; mRNA.
DR EMBL; Z98949; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR EMBL; AL080245; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR EMBL; AL022329; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR EMBL; AL079300; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR EMBL; KF457380; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR EMBL; KF457381; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR EMBL; KF457390; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR EMBL; KF511427; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR EMBL; BC144597; AAI44598.1; -; mRNA.
DR EMBL; BC150626; AAI50627.1; -; mRNA.
DR EMBL; AJ271918; CAC81082.1; -; mRNA.
DR EMBL; AL833890; CAD38746.1; -; mRNA.
DR CCDS; CCDS54507.1; -. [Q8IUG5-1]
DR CCDS; CCDS82703.1; -. [Q8IUG5-3]
DR RefSeq; NP_001305174.1; NM_001318245.1. [Q8IUG5-3]
DR RefSeq; NP_115997.5; NM_032608.6. [Q8IUG5-1]
DR AlphaFoldDB; Q8IUG5; -.
DR SMR; Q8IUG5; -.
DR BioGRID; 124214; 7.
DR IntAct; Q8IUG5; 6.
DR STRING; 9606.ENSP00000334563; -.
DR iPTMnet; Q8IUG5; -.
DR PhosphoSitePlus; Q8IUG5; -.
DR BioMuta; MYO18B; -.
DR DMDM; 32699565; -.
DR EPD; Q8IUG5; -.
DR jPOST; Q8IUG5; -.
DR MassIVE; Q8IUG5; -.
DR PaxDb; Q8IUG5; -.
DR PeptideAtlas; Q8IUG5; -.
DR PRIDE; Q8IUG5; -.
DR ProteomicsDB; 24501; -.
DR ProteomicsDB; 24848; -.
DR ProteomicsDB; 70563; -. [Q8IUG5-1]
DR ProteomicsDB; 70564; -. [Q8IUG5-2]
DR Antibodypedia; 264; 73 antibodies from 21 providers.
DR DNASU; 84700; -.
DR Ensembl; ENST00000335473.12; ENSP00000334563.8; ENSG00000133454.16. [Q8IUG5-1]
DR Ensembl; ENST00000407587.6; ENSP00000386096.2; ENSG00000133454.16. [Q8IUG5-3]
DR Ensembl; ENST00000536101.5; ENSP00000441229.1; ENSG00000133454.16. [Q8IUG5-1]
DR GeneID; 84700; -.
DR KEGG; hsa:84700; -.
DR MANE-Select; ENST00000335473.12; ENSP00000334563.8; NM_032608.7; NP_115997.5.
DR UCSC; uc003abz.1; human.
DR UCSC; uc062com.1; human. [Q8IUG5-1]
DR CTD; 84700; -.
DR DisGeNET; 84700; -.
DR GeneCards; MYO18B; -.
DR HGNC; HGNC:18150; MYO18B.
DR HPA; ENSG00000133454; Tissue enhanced (heart muscle, skeletal muscle, tongue).
DR MalaCards; MYO18B; -.
DR MIM; 607295; gene.
DR MIM; 616549; phenotype.
DR neXtProt; NX_Q8IUG5; -.
DR OpenTargets; ENSG00000133454; -.
DR Orphanet; 447974; Klippel-Feil anomaly-myopathy-facial dysmorphism syndrome.
DR PharmGKB; PA38300; -.
DR VEuPathDB; HostDB:ENSG00000133454; -.
DR eggNOG; KOG0161; Eukaryota.
DR GeneTree; ENSGT00940000158067; -.
DR HOGENOM; CLU_1326008_0_0_1; -.
DR InParanoid; Q8IUG5; -.
DR OMA; AMQLECC; -.
DR OrthoDB; 34123at2759; -.
DR PhylomeDB; Q8IUG5; -.
DR TreeFam; TF339614; -.
DR PathwayCommons; Q8IUG5; -.
DR SignaLink; Q8IUG5; -.
DR BioGRID-ORCS; 84700; 11 hits in 1075 CRISPR screens.
DR ChiTaRS; MYO18B; human.
DR GeneWiki; MYO18B; -.
DR GenomeRNAi; 84700; -.
DR Pharos; Q8IUG5; Tbio.
DR PRO; PR:Q8IUG5; -.
DR Proteomes; UP000005640; Chromosome 22.
DR RNAct; Q8IUG5; protein.
DR Bgee; ENSG00000133454; Expressed in apex of heart and 98 other tissues.
DR ExpressionAtlas; Q8IUG5; baseline and differential.
DR Genevisible; Q8IUG5; HS.
DR GO; GO:0031941; C:filamentous actin; IEA:Ensembl.
DR GO; GO:0032982; C:myosin filament; IBA:GO_Central.
DR GO; GO:0016460; C:myosin II complex; IBA:GO_Central.
DR GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR GO; GO:0016461; C:unconventional myosin complex; IDA:UniProtKB.
DR GO; GO:0030018; C:Z disc; IEA:Ensembl.
DR GO; GO:0051015; F:actin filament binding; IBA:GO_Central.
DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR GO; GO:0003774; F:cytoskeletal motor activity; IEA:InterPro.
DR GO; GO:0031032; P:actomyosin structure organization; IBA:GO_Central.
DR GO; GO:0055013; P:cardiac muscle cell development; IEA:Ensembl.
DR GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR GO; GO:0001570; P:vasculogenesis; IEA:Ensembl.
DR CDD; cd01386; MYSc_Myo18; 1.
DR Gene3D; 3.40.850.10; -; 1.
DR InterPro; IPR000048; IQ_motif_EF-hand-BS.
DR InterPro; IPR036961; Kinesin_motor_dom_sf.
DR InterPro; IPR028561; MYO18B.
DR InterPro; IPR001609; Myosin_head_motor_dom.
DR InterPro; IPR036064; MYSc_Myo18.
DR InterPro; IPR027417; P-loop_NTPase.
DR PANTHER; PTHR45615:SF8; PTHR45615:SF8; 1.
DR Pfam; PF00063; Myosin_head; 1.
DR PRINTS; PR00193; MYOSINHEAVY.
DR SMART; SM00242; MYSc; 1.
DR SUPFAM; SSF52540; SSF52540; 1.
DR PROSITE; PS50096; IQ; 1.
DR PROSITE; PS51456; MYOSIN_MOTOR; 1.
PE 1: Evidence at protein level;
KW Actin-binding; Alternative splicing; ATP-binding; Coiled coil; Cytoplasm;
KW Motor protein; Myosin; Nucleotide-binding; Nucleus; Phosphoprotein;
KW Reference proteome.
FT CHAIN 1..2567
FT /note="Unconventional myosin-XVIIIb"
FT /id="PRO_0000123478"
FT DOMAIN 571..1333
FT /note="Myosin motor"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00782"
FT DOMAIN 1336..1365
FT /note="IQ"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00116"
FT REGION 41..508
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 1208..1232
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 1213..1240
FT /note="GPA"
FT /evidence="ECO:0000255"
FT REGION 1426..2083
FT /note="Tail"
FT REGION 2139..2194
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 2217..2249
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 2357..2376
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 2444..2471
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 2494..2567
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COILED 1396..1783
FT /evidence="ECO:0000255"
FT COILED 1825..1961
FT /evidence="ECO:0000255"
FT COILED 2014..2090
FT /evidence="ECO:0000255"
FT COMPBIAS 43..62
FT /note="Basic and acidic residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 69..108
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 115..140
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 328..344
FT /note="Basic and acidic residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 347..361
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 467..489
FT /note="Basic and acidic residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 2139..2156
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 2165..2188
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 2219..2242
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 2357..2374
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 2453..2471
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 2505..2521
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 2538..2561
FT /note="Basic and acidic residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT BINDING 660..667
FT /ligand="ATP"
FT /ligand_id="ChEBI:CHEBI:30616"
FT /evidence="ECO:0000255"
FT MOD_RES 1216
FT /note="Phosphoserine"
FT /evidence="ECO:0007744|PubMed:23186163"
FT MOD_RES 1829
FT /note="Phosphoserine"
FT /evidence="ECO:0007744|PubMed:18669648"
FT MOD_RES 2193
FT /note="Phosphoserine"
FT /evidence="ECO:0007744|PubMed:23186163"
FT MOD_RES 2296
FT /note="Phosphoserine"
FT /evidence="ECO:0007744|PubMed:23186163"
FT MOD_RES 2309
FT /note="Phosphoserine"
FT /evidence="ECO:0007744|PubMed:23186163"
FT MOD_RES 2377
FT /note="Phosphoserine"
FT /evidence="ECO:0007744|PubMed:23186163"
FT VAR_SEQ 1..487
FT /note="Missing (in isoform 2)"
FT /evidence="ECO:0000303|PubMed:12209013"
FT /id="VSP_007764"
FT VAR_SEQ 488..503
FT /note="PAPQEEGKGGQSRDSD -> MGSGAICWFNLRDVGS (in isoform 2)"
FT /evidence="ECO:0000303|PubMed:12209013"
FT /id="VSP_007765"
FT VAR_SEQ 1019
FT /note="S -> SQ (in isoform 3)"
FT /evidence="ECO:0000305"
FT /id="VSP_059434"
FT VARIANT 44
FT /note="G -> E (in dbSNP:rs133885)"
FT /id="VAR_056190"
FT VARIANT 177
FT /note="P -> L (in dbSNP:rs13058434)"
FT /id="VAR_056191"
FT VARIANT 234
FT /note="G -> V (in a lung small cell carcinoma sample;
FT somatic mutation)"
FT /evidence="ECO:0000269|PubMed:12209013"
FT /id="VAR_015862"
FT VARIANT 347
FT /note="K -> N (in a lung small cell carcinoma sample;
FT somatic mutation)"
FT /evidence="ECO:0000269|PubMed:12209013"
FT /id="VAR_015863"
FT VARIANT 379
FT /note="R -> Q (in a lung small cell carcinoma sample;
FT somatic mutation; dbSNP:rs750078923)"
FT /evidence="ECO:0000269|PubMed:12209013"
FT /id="VAR_015864"
FT VARIANT 389
FT /note="W -> C (in a lung adenocarcinoma sample; somatic
FT mutation)"
FT /evidence="ECO:0000269|PubMed:12209013"
FT /id="VAR_015865"
FT VARIANT 547
FT /note="W -> C (in dbSNP:rs3859866)"
FT /evidence="ECO:0000269|PubMed:15489334, ECO:0000269|Ref.3"
FT /id="VAR_056192"
FT VARIANT 590
FT /note="T -> M (in a lung large cell carcinoma sample;
FT somatic mutation; dbSNP:rs370187232)"
FT /evidence="ECO:0000269|PubMed:12209013"
FT /id="VAR_015866"
FT VARIANT 661
FT /note="W -> R (in dbSNP:rs5761170)"
FT /evidence="ECO:0000269|PubMed:12547197,
FT ECO:0000269|PubMed:15489334, ECO:0000269|Ref.3"
FT /id="VAR_015867"
FT VARIANT 835
FT /note="A -> G (in a lung squamous cell carcinoma sample;
FT somatic mutation)"
FT /evidence="ECO:0000269|PubMed:12209013"
FT /id="VAR_015868"
FT VARIANT 925
FT /note="S -> L (in dbSNP:rs9624909)"
FT /evidence="ECO:0000269|PubMed:12547197"
FT /id="VAR_056193"
FT VARIANT 1037
FT /note="W -> S (in dbSNP:rs17704912)"
FT /id="VAR_056194"
FT VARIANT 1095
FT /note="R -> L (in a lung adenocarcinoma sample; somatic
FT mutation)"
FT /evidence="ECO:0000269|PubMed:12209013"
FT /id="VAR_015869"
FT VARIANT 1119
FT /note="H -> Q (in dbSNP:rs5761268)"
FT /evidence="ECO:0000269|PubMed:15489334, ECO:0000269|Ref.3"
FT /id="VAR_056195"
FT VARIANT 1195
FT /note="R -> Q (in a lung small cell carcinoma sample;
FT somatic mutation; dbSNP:rs1429133479)"
FT /evidence="ECO:0000269|PubMed:12209013"
FT /id="VAR_015870"
FT VARIANT 1238
FT /note="P -> Q (in a lung large cell carcinoma sample;
FT somatic mutation)"
FT /evidence="ECO:0000269|PubMed:12209013"
FT /id="VAR_015871"
FT VARIANT 1238
FT /note="P -> T (in a lung adenocarcinoma sample; somatic
FT mutation)"
FT /evidence="ECO:0000269|PubMed:12209013"
FT /id="VAR_015872"
FT VARIANT 1390
FT /note="S -> F (in dbSNP:rs35578357)"
FT /id="VAR_056196"
FT VARIANT 1399
FT /note="I -> V (in dbSNP:rs695633)"
FT /id="VAR_056197"
FT VARIANT 1444
FT /note="S -> T (in dbSNP:rs33928909)"
FT /id="VAR_056198"
FT VARIANT 1708
FT /note="E -> K (in a lung adenocarcinoma sample; somatic
FT mutation)"
FT /evidence="ECO:0000269|PubMed:12209013"
FT /id="VAR_015873"
FT VARIANT 1715
FT /note="E -> D (in a lung adenocarcinoma sample; somatic
FT mutation)"
FT /evidence="ECO:0000269|PubMed:12209013"
FT /id="VAR_015874"
FT VARIANT 1970
FT /note="A -> E (in a lung small cell carcinoma sample;
FT somatic mutation)"
FT /evidence="ECO:0000269|PubMed:12209013"
FT /id="VAR_015875"
FT VARIANT 2294
FT /note="A -> D (in dbSNP:rs35370367)"
FT /id="VAR_056199"
FT VARIANT 2295
FT /note="G -> C (in a lung small cell carcinoma sample;
FT somatic mutation)"
FT /evidence="ECO:0000269|PubMed:12209013"
FT /id="VAR_015876"
FT VARIANT 2347
FT /note="Q -> R (in dbSNP:rs2236005)"
FT /evidence="ECO:0000269|PubMed:15489334"
FT /id="VAR_015877"
FT VARIANT 2381
FT /note="R -> H (in a lung adenocarcinoma sample; somatic
FT mutation; dbSNP:rs200567905)"
FT /evidence="ECO:0000269|PubMed:12209013"
FT /id="VAR_015878"
FT VARIANT 2395
FT /note="G -> A (in dbSNP:rs6004901)"
FT /id="VAR_056200"
FT VARIANT 2513
FT /note="G -> S (in dbSNP:rs7284177)"
FT /id="VAR_056201"
FT VARIANT 2532
FT /note="R -> Q (in dbSNP:rs34875296)"
FT /id="VAR_056202"
FT VARIANT 2554
FT /note="D -> E (in a lung large cell carcinoma sample;
FT somatic mutation; dbSNP:rs780180192)"
FT /evidence="ECO:0000269|PubMed:12209013"
FT /id="VAR_015879"
FT CONFLICT 3
FT /note="I -> M (in Ref. 2; CAC70712)"
FT /evidence="ECO:0000305"
FT CONFLICT 828
FT /note="A -> T (in Ref. 6; AAI50627/AAI44598)"
FT /evidence="ECO:0000305"
FT CONFLICT 1020
FT /note="Q -> QQ (in Ref. 3; AAL75811)"
FT /evidence="ECO:0000305"
FT CONFLICT 1060
FT /note="A -> T (in Ref. 3; AAL75811)"
FT /evidence="ECO:0000305"
FT CONFLICT 1510
FT /note="N -> D (in Ref. 3; AAL75811)"
FT /evidence="ECO:0000305"
FT CONFLICT 1515
FT /note="Missing (in Ref. 6; AAI50627/AAI44598)"
FT /evidence="ECO:0000305"
FT CONFLICT 2343..2344
FT /note="KS -> LT (in Ref. 5)"
FT /evidence="ECO:0000305"
SQ SEQUENCE 2567 AA; 285215 MW; C36BFD5C6FB4258B CRC64;
MAISSRLALW EQKIREEDKS PPPSSPPPLF SVIPGGFIKQ LVRGTEKEAK EARQRKQLAV
ASPEREIPEI SISQPNSKSS SGTRSGSQQI SQDDQSSSPG SSDILGKESE GSRSPDPEQM
TSINGEKAQE LGSSATPTKK TVPFKRGVRR GDVLLMVAKL DPDSAKPEKT HPHDAPPCKT
SPPATDTGKE KKGETSRTPC GSQASTEILA PKAEKTRTGG LGDPGQGTVA LKKGEEGQSI
VGKGLGTPKT TELKEAEPQG KDRQGTRPQA QGPGEGVRPG KAEKEGAEPT NTVEKGNVSK
DVGSEGKHVR PQIPGRKWGG FLGRRSKWDG PQNKKDKEGV LLSKAEKTGE PQTQMEKTSQ
VQGELGDDLR MGEKAGELRS TTGKAGESWD KKEKMGQPQG KSGNAGEARS QTEKGCEAPK
EVSTMVESPA APGKGGWPGS RGQEAEEPCS RAGDGAGALE TELEGPSQPA LEKDAERPRI
RKENQDGPAP QEEGKGGQSR DSDQAPEDRW YEAEKVWLAQ KDGFTLATVL KPDEGTADLP
AGRVRLWIDA DKTITEVDEE HVHRANPPEL DQVEDLASLI SVNESSVLNT LLQRYKAQLL
HTCTGPDLIV LQPRGPSVPS AGKVPKGRRD GLPAHIGSMA QRAYWALLNQ RRDQSIVALG
WSGAGKTTCC EQVLEHLVGM AGSVDGRVSV EKIRATFTVL RAFGSVSMAH SRSATRFSMV
MSLDFNATGR ITAAQLQTML LEKSRVARQP EGESNFLVFS QMLAGLDLDL RTELNLHQMA
DSSSFGMGVW SKPEDKQKAA AAFAQLQGAM EMLGISESEQ RAVWRVLAAI YHLGAAGACK
VGRKQFMRFE WANYAAEALG CEYEELNTAT FKHHLRQIIQ QMTFGPSRWG LEDEETSSGL
KMTGVDCVEG MASGLYQELF AAVVSLINRS FSSHHLSMAS IMVVDSPGFQ NPRHQGKDRA
ATFEELCHNY AHERLQLLFY QRTFVSTLQR YQEEGVPVQF DLPDPSPGTT VAVVDQNPSQ
VRLPAGGGAQ DARGLFWVLD EEVHVEGSSD SVVLERLCAA FEKKGAGTEG SSALRTCEQP
LQCEIFHQLG WDPVRYDLTG WLHRAKPNLS ALDAPQVLHQ SKREELRSLF QARAKLPPVC
RAVAGLEGTS QQALQRSRMV RRTFASSLAA VRRKAPCSQI KLQMDALTSM IKRSRLHFIH
CLVPNPVVES RSGQESPPPP QPGRDKPGAG GPLALDIPAL RVQLAGFHIL EALRLHRTGY
ADHMGLTRFR RQFQVLDAPL LKKLMSTSEG IDERKAVEEL LETLDLEKKA VAVGHSQVFL
KAGVISRLEK QREKLVSQSI VLFQAACKGF LSRQEFKKLK IRRLAAQCIQ KNVAVFLAVK
DWPWWQLLGS LQPLLSATIG TEQLRAKEEE LTTLRRKLEK SEKLRNELRQ NTDLLESKIA
DLTSDLADER FKGDVACQVL ESERAERLQA FREVQELKSK HEQVQKKLGD VNKQLEEAQQ
KIQLNDLERN PTGGADEWQM RFDCAQMENE FLRKRLQQCE ERLDSELTAR KELEQKLGEL
QSAYDGAKKM AHQLKRKCHH LTCDLEDTCV LLENQQSRNH ELEKKQKKFD LQLAQALGES
VFEKGLREKV TQENTSVRWE LGQLQQQLKQ KEQEASQLKQ QVEMLQDHKR ELLGSPSLGE
NCVAGLKERL WKLESSALEQ QKIQSQQENT IKQLEQLRQR FELEIERMKQ MHQKDREDQE
EELEDVRQSC QKRLHQLEMQ LEQEYEEKQM VLHEKQDLEG LIGTLCDQIG HRDFDVEKRL
RRDLRRTHAL LSDVQLLLGT MEDGKTSVSK EELEKVHSQL EQSEAKCEEA LKTQKVLTAD
LESMHSELEN MTRNKSLVDE QLYRLQFEKA DLLKRIDEDQ DDLNELMQKH KDLIAQSAAD
IGQIQELQLQ LEEAKKEKHK LQEQLQVAQM RIEYLEQSTV DRAIVSRQEA VICDLENKTE
FQKVQIKRFE VLVIRLRDSL IKMGEELSQA ATSESQQRES SQYYQRRLEE LKADMEELVQ
REAEASRRCM ELEKYVEELA AVRQTLQTDL ETSIRRIADL QAALEEVASS DSDTESVQTA
VDCGSSGRKE MDNVSILSSQ PEGSLQSWLS CTLSLATDTM RTPSRQSATS SRILSPRINE
EAGDTERTQS ALALSRARST NVHSKTSGDK PVSPHFVRRQ KYCHFGDGEV LAVQRKSTER
LEPASSPLAS RSTNTSPLSR EKLPSPSAAL SEFVEGLRRK RAQRGQGSTL GLEDWPTLPI
YQTTGASTLR RGRAGSDEGN LSLRVGAKSP LEIEGAAGGL LRSTSLKCIS SDGVGGTTLL
PEKSKTQFSS CESLLESRPS MGRKLSSPTT PRDMLLSPTL RPRRRCLESS VDDAGCPDLG
KEPLVFQNRQ FAHLMEEPLG SDPFSWKLPS LDYERKTKVD FDDFLPAIRK PQTPTSLAGS
AKGGQDGSQR SSIHFETEEA NRSFLSGIKT ILKKSPEPKE DPAHLSDSSS SSGSIVSFKS
ADSIKSRPGI PRLAGDGGER TSPERREPGT GRKDDDVASI MKKYLQK
